Developer docs
API playgroundTry for free, no card

Search company profiles

Elpiscience Biopharmaceuticals

Full company profile

uuid0000z6d

Namestring
Elpiscience Biopharmaceuticals
Legal namestring
Elpiscience Biopharma, Ltd.
Websiteurl
elpiscience.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Elpiscience Biopharmaceuticals is a clinical-stage biopharmaceutical company founded in June 2017 in Shanghai, China, focused on developing next-generation immunotherapies for oncology and autoimmune diseases. The company is building a pipeline of 15+ globally innovative molecules led by multiple bispecific antibody programs, including ES101 (PD-L1/4-1BB tetravalent), ES102 (hexavalent OX40 agonist), ES104 (VEGF/DLL4), ES002 (anti-CD39), ES014 (CD39/TGF-β), ES009 (anti-LILRB2), and ES019 (PD-L1/SIRPα), plus preclinical programs ES004, ES015, ES038, and ES302 (TL1A/IL23p19 for IBD). Its core proprietary technology is the BiME® (Bispecific Macrophage Engager) platform, which generates bispecific antibodies engaging SIRPα on tumor-associated macrophages alongside tumor-associated antigens to activate phagocytosis and overcome the CD47-SIRPα 'don't eat me' signal.

The company's go-to-market combines direct clinical development with a global partnership/licensing model: Elpiscience retains Greater China rights for selected assets (e.g., ES104) and out-licenses regional or global rights to major pharmaceutical partners including Astellas (BiME programs ex-Greater China), Compass Therapeutics (ES104 Greater China via the legacy TRIGR deal), Inhibrx (in-licensed ES101/ES102), and Junshi Biosciences (ES102 + toripalimab combination). Operations span Shanghai (HQ, Pudong), Suzhou (R&D center in Zhangjiang High-Tech Park), Maryland (US), and Australia, with clinical trials conducted across the US, China, and Australia under parallel FDA and CDE regulatory pathways.

Elpiscience remains pre-revenue, generating no current product sales; future revenue is expected from product commercialization following regulatory approval and from licensing milestones/royalties under existing partnerships. The company is venture capital-backed, having raised approximately $260 million USD across Series A ($20M, August 2017), Series A+ ($35M, December 2018), Series B ($100M, December 2019), and Series C ($105M, May 2021) rounds, with investor syndicate including Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH Investments, Tencent, and Cormorant Asset Management. Recent clinical milestones include ES104's Phase 2/3 BTC primary endpoint hit (17.1% ORR vs 5.3% paclitaxel), ES014's FDA Orphan Drug Designation for desmoid tumors with 40% ORR/100% DCR in Phase I, and SITC 2025 Top 150 Abstract recognition.

Short descriptiontext

Elpiscience Biopharmaceuticals is a clinical-stage Chinese biopharmaceutical company developing next-generation bispecific antibody immunotherapies for oncology and autoimmune diseases, leveraging a proprietary BiME® macrophage engager platform and a 15+ molecule pipeline targeting unmet needs in cold tumors and IBD.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody development, cancer immunotherapy pipeline, immuno-oncology therapeutics, monoclonal antibody drugs, biopharmaceutical clinical research
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing innovative immunotherapies for oncology and autoimmune diseases. Revenue will be generated through eventual product sales following regulatory approval and commercialization.

elpiscience.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1BiME®
Description

Bispecific Macrophage Engager platform technology that activates tumor-associated macrophages for solid tumor killing.

elpiscience.com
+2 more records
Core offering1 text field

Elpiscience is a clinical-stage biopharmaceutical company that develops next-generation immunotherapies for oncology and autoimmune diseases. Its core offering is a pipeline of innovative bispecific and monoclonal antibody therapeutics targeting immune checkpoints, the tumor microenvironment, and key cytokine pathways, generated through its proprietary BiME® macrophage engager platform and integrated antibody discovery engine. The company advances these programs through preclinical and clinical development with global strategic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ES104 achieved 19% ORR at RP2D (10.0-12.5 mg/kg) with 69% DCR in heavily pre-treated patients with colorectal and gastric cancers
+3 more records
Product overview1 text field

Elpiscience is a clinical-stage biopharmaceutical company pioneering a globally leading pipeline of innovative immunotherapies focused on oncology and autoimmune diseases. The company's core portfolio includes multiple bispecific antibody programs: ES101 (PD-L1/4-1BB) and ES102 (OX40 agonist) partnered with Inhibrx; ES104 (VEGF/DLL4) partnered with Compass Therapeutics for Greater China rights; ES002 (anti-CD39) and ES014 (CD39/TGF-β) in clinical development; ES009 (anti-LILRB2) and ES019 (PD-L1/SIRPα BiME®) advancing through clinical stages; plus ES004, ES015, and ES038 in preclinical development. The proprietary BiME® (Bispecific Macrophage Engager) platform enables generation of bispecific antibodies targeting tumor-associated macrophages. The company also has an autoimmune program ES302 targeting TL1A and IL23p19 for IBD. Elpiscience leverages integrated R&D capabilities combining proprietary antibody discovery, translational research, and clinical development.

Product and service11 records
1ES101
CategoryClinical-stage bispecific antibody
Description

First-in-class tetravalent bispecific antibody targeting both PD-L1 and 4-1BB, designed on the 'de-brake and add gas' concept for immune cell activation. Conditionally activates 4-1BB upon binding to PD-L1 in the tumor microenvironment. In-licensed from Inhibrx for Greater China.

2ES102 (INBRX-106)
CategoryClinical-stage bispecific antibody
Description

Hexavalent OX40 agonist antibody with first-in-class design consisting of six OX40 single-domain antibody structures. Induces stronger downstream signaling than bivalent antibodies and demonstrates synergy with anti-PD-1/PD-L1 agents. In-licensed from Inhibrx for Greater China.

3ES104 (CTX-009/ABL001/TR009)
CategoryClinical-stage bispecific antibody
Description

Bispecific antibody targeting both VEGF and DLL4/Notch pathways, designed to overcome multi-VEGF resistance. Demonstrated clinical activity in heavily pre-treated patients with solid tumors resistant to anti-VEGF therapies. Elpiscience holds Greater China rights.

4ES002
CategoryClinical-stage monoclonal antibody
Description

Potentially best-in-class anti-CD39 monoclonal antibody that reverses suppressive tumor microenvironment by blocking CD39 function, stabilizing pro-inflammatory extracellular ATP (eATP), and restoring anti-tumor immunity. Internally discovered by Elpiscience.

5ES014
CategoryClinical-stage bispecific antibody
Description

First-in-class anti-CD39xTGF-β bispecific antibody that simultaneously targets CD39-adenosine and TGF-β pathways. Designed to create an immune-favorable tumor microenvironment by inhibiting adenosine generation and neutralizing immunosuppressive TGF-β. Received FDA Orphan Drug Designation for desmoid tumors.

6ES009
CategoryClinical-stage monoclonal antibody
Description

Anti-LILRB2 (ILT4) monoclonal antibody that reprograms immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages. Demonstrated best-in-class potential in preclinical studies with ability to reverse immune suppression in tumor microenvironment. First-in-human studies conducted in Australia.

7ES019 (BiME®)
CategoryClinical-stage bispecific antibody
Description

PD-L1/SIRPα bispecific antibody generated from proprietary BiME® platform. Simultaneously reactivates macrophages and T cells for tumor elimination by targeting both tumor cells and immune cells. Out-licensed to Astellas for development and commercialization outside Greater China.

8ES004
CategoryPreclinical-stage antibody
Description

Anti-SIRPα antibody with unique pan-allelic binding properties (ES004-B4 and ES004-N4 variants). Blocks CD47-SIRPα 'don't eat me' signaling and enhances macrophage-mediated tumor cell destruction through different mechanisms.

9ES015
CategoryPreclinical-stage bispecific antibody
Description

First-in-class NKG2A and NKG2C dual-targeting antibody that inhibits NKG2A function while promoting NKG2C action, leading to superior anti-tumor response through NK and CD8 T cell activation.

10ES038
CategoryPreclinical-stage NK cell engager
Description

Novel NK cell engager (NKCE) targeting LILRB4 on AML cells while simultaneously blocking inhibitory (NKG2A) and stimulating (NKG2C) receptors on NK cells. Dual-targeting strategy enhances NK cell activation for AML treatment.

11ES302
CategoryPreclinical-stage bispecific antibody
Description

Next-generation bispecific antibody targeting TL1A and IL23p19 for inflammatory bowel disease (IBD) therapy. Dual-targeting approach blocks two critical cytokine pathways with engineered subcutaneous administration, long-acting profile, and superior resistance to enzymatic degradation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-12-28
Description

Research collaboration and license agreement for novel bi-specific macrophage engagers (BiME), ES019 and another program. Companies will collaboratively conduct early-stage research. Elpiscience grants Astellas the right to add up to two additional programs. If Astellas exercises its option, Elpiscience will grant exclusive rights to further research, develop, manufacture and commercialize.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-20
Description

Exclusive licensing agreement for ES104/TR009 in Greater China for development, manufacture and commercialization. TRIGR received $7 million upfront and eligible for $110 million in milestones plus royalties. Elpiscience leads clinical development in Greater China leveraging translational science, clinical and regulatory experience.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-05-28
Description

Clinical collaboration to evaluate ES102 (next-generation OX40 agonistic antibody) in combination with toripalimab (TUOYI, anti-PD-1 mAb) for treatment of solid tumors and hematological malignancies.

Strategic tierMinorTypeOthersAnnounced on2019-07-16
Description

R&D center location in Zhangjiang High-Tech Park, China's most advanced innovation center for biomedical industry.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-03-01
Description

Exclusive licensing agreement for ES101 (INBRX-105/PD-L1 and 4-1BB bispecific) in Greater China. Also partnered on ES102 (INBRX-106/hexavalent OX40 agonist) in Greater China.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1I-Mab Biopharma
TypeDirect peer
Description

China- and US-based clinical-stage biopharmaceutical company focused on immuno-oncology biologics. I-Mab's pipeline of monoclonal and bispecific antibodies targeting similar pathways (CD47, PD-L1, 4-1BB) overlaps with Elpiscience's programs.

TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company developing a broad pipeline of innovative bispecific and multispecific antibodies for oncology and autoimmune diseases. Akeso is a leading domestic competitor in the Chinese bispecific antibody space with overlapping therapeutic targets.

TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company developing immuno-oncology agents including PD-L1 antibody (sugemalimab) and bispecifics. CStone competes with Elpiscience in the Chinese immuno-oncology market with overlapping indications.

TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company focused on bispecific antibodies and antibody-drug conjugates for oncology. Alphamab has overlapping platform technologies (knob-into-hole bispecifics) and competes in similar indications including solid tumors.

TypeDirect peer
Description

Boston-based clinical-stage bispecific antibody developer and direct partner of Elpiscience (holds global ex-Greater China/South Korea rights to ES104). Compass has a similar pipeline of next-generation immuno-oncology bispecifics including CTX-009/ES104, making it a directly comparable peer.

TypeBroad incumbent
Description

Global oncology-focused biotechnology company with approved BTK inhibitor (zanubrutinib) and PD-1 antibody (tislelizumab). While broader in scope than Elpiscience, BeiGene represents a major Chinese biopharma competitor with significantly greater commercialization scale and resources.

7Genor Biopharma
TypeDirect peer
Description

China-based biopharmaceutical company developing innovative therapeutics for oncology and autoimmune diseases, with a pipeline of monoclonal antibodies and bispecifics. Comparable in stage and therapeutic focus to Elpiscience's clinical-stage portfolio.

TypeEmerging player
Description

China-based innovation-driven biopharmaceutical company and Elpiscience's collaboration partner (ES102 + toripalimab combinations). Junshi's anti-PD-1 antibody toripalimab anchors multiple combination strategies in solid tumors, overlapping with Elpiscience's combination development.

TypeEmerging player
Description

US-based clinical-stage immuno-oncology company developing novel biologics targeting myeloid immune checkpoints. NextCure's focus on tumor microenvironment and innate immunity modulation overlaps with Elpiscience's BiME® macrophage-engager approach.

TypeDirect peer
Description

Clinical-stage biotechnology company developing next-generation biologics including bispecific antibodies. Inhibrx is a direct licensor/partner of Elpiscience (ES101/INBRX-105 and ES102/INBRX-106 for Greater China) with highly comparable single-domain antibody platform technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elpiscience Biopharmaceuticals

Cancer Immunotherapyelpiscience.com

Elpiscience Biopharmaceuticals is a clinical-stage Chinese biopharmaceutical company developing next-generation bispecific antibody immunotherapies for oncology and autoimmune diseases, leveraging a proprietary BiME® macrophage engager platform and a 15+ molecule pipeline targeting unmet needs in cold tumors and IBD.

What Elpiscience Biopharmaceuticals does

Elpiscience Biopharmaceuticals is a clinical-stage biopharmaceutical company founded in June 2017 in Shanghai, China, focused on developing next-generation immunotherapies for oncology and autoimmune diseases. The company is building a pipeline of 15+ globally innovative molecules led by multiple bispecific antibody programs, including ES101 (PD-L1/4-1BB tetravalent), ES102 (hexavalent OX40 agonist), ES104 (VEGF/DLL4), ES002 (anti-CD39), ES014 (CD39/TGF-β), ES009 (anti-LILRB2), and ES019 (PD-L1/SIRPα), plus preclinical programs ES004, ES015, ES038, and ES302 (TL1A/IL23p19 for IBD). Its core proprietary technology is the BiME® (Bispecific Macrophage Engager) platform, which generates bispecific antibodies engaging SIRPα on tumor-associated macrophages alongside tumor-associated antigens to activate phagocytosis and overcome the CD47-SIRPα 'don't eat me' signal.

The company's go-to-market combines direct clinical development with a global partnership/licensing model: Elpiscience retains Greater China rights for selected assets (e.g., ES104) and out-licenses regional or global rights to major pharmaceutical partners including Astellas (BiME programs ex-Greater China), Compass Therapeutics (ES104 Greater China via the legacy TRIGR deal), Inhibrx (in-licensed ES101/ES102), and Junshi Biosciences (ES102 + toripalimab combination). Operations span Shanghai (HQ, Pudong), Suzhou (R&D center in Zhangjiang High-Tech Park), Maryland (US), and Australia, with clinical trials conducted across the US, China, and Australia under parallel FDA and CDE regulatory pathways.

Elpiscience remains pre-revenue, generating no current product sales; future revenue is expected from product commercialization following regulatory approval and from licensing milestones/royalties under existing partnerships. The company is venture capital-backed, having raised approximately $260 million USD across Series A ($20M, August 2017), Series A+ ($35M, December 2018), Series B ($100M, December 2019), and Series C ($105M, May 2021) rounds, with investor syndicate including Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH Investments, Tencent, and Cormorant Asset Management. Recent clinical milestones include ES104's Phase 2/3 BTC primary endpoint hit (17.1% ORR vs 5.3% paclitaxel), ES014's FDA Orphan Drug Designation for desmoid tumors with 40% ORR/100% DCR in Phase I, and SITC 2025 Top 150 Abstract recognition.

Elpiscience Biopharmaceuticals firmographics

Firmographics
Name
Elpiscience Biopharmaceuticals
Legal name
Elpiscience Biopharma, Ltd.
Website
https://elpiscience.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Elpiscience Biopharmaceuticals is a clinical-stage Chinese biopharmaceutical company developing next-generation bispecific antibody immunotherapies for oncology and autoimmune diseases, leveraging a proprietary BiME® macrophage engager platform and a 15+ molecule pipeline targeting unmet needs in cold tumors and IBD.
Ownership category
akta.pro rank

Where Elpiscience Biopharmaceuticals is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Elpiscience Biopharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing innovative immunotherapies for oncology and autoimmune diseases. Revenue will be generated through eventual product sales following regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Elpiscience Biopharmaceuticals product offering

Product offering

Core offering

Elpiscience is a clinical-stage biopharmaceutical company that develops next-generation immunotherapies for oncology and autoimmune diseases. Its core offering is a pipeline of innovative bispecific and monoclonal antibody therapeutics targeting immune checkpoints, the tumor microenvironment, and key cytokine pathways, generated through its proprietary BiME® macrophage engager platform and integrated antibody discovery engine. The company advances these programs through preclinical and clinical development with global strategic partners.

Product overview

Elpiscience is a clinical-stage biopharmaceutical company pioneering a globally leading pipeline of innovative immunotherapies focused on oncology and autoimmune diseases. The company's core portfolio includes multiple bispecific antibody programs: ES101 (PD-L1/4-1BB) and ES102 (OX40 agonist) partnered with Inhibrx; ES104 (VEGF/DLL4) partnered with Compass Therapeutics for Greater China rights; ES002 (anti-CD39) and ES014 (CD39/TGF-β) in clinical development; ES009 (anti-LILRB2) and ES019 (PD-L1/SIRPα BiME®) advancing through clinical stages; plus ES004, ES015, and ES038 in preclinical development. The proprietary BiME® (Bispecific Macrophage Engager) platform enables generation of bispecific antibodies targeting tumor-associated macrophages. The company also has an autoimmune program ES302 targeting TL1A and IL23p19 for IBD. Elpiscience leverages integrated R&D capabilities combining proprietary antibody discovery, translational research, and clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • BiME®: Bispecific Macrophage Engager platform technology that activates tumor-associated macrophages for solid tumor killing.
  • ES014
  • ES104

Products and services

  • ES101 First-in-class tetravalent bispecific antibody targeting both PD-L1 and 4-1BB, designed on the 'de-brake and add gas' concept for immune cell activation. Conditionally activates 4-1BB upon binding to PD-L1 in the tumor microenvironment. In-licensed from Inhibrx for Greater China.
  • ES102 (INBRX-106) Hexavalent OX40 agonist antibody with first-in-class design consisting of six OX40 single-domain antibody structures. Induces stronger downstream signaling than bivalent antibodies and demonstrates synergy with anti-PD-1/PD-L1 agents. In-licensed from Inhibrx for Greater China.
  • ES104 (CTX-009/ABL001/TR009) Bispecific antibody targeting both VEGF and DLL4/Notch pathways, designed to overcome multi-VEGF resistance. Demonstrated clinical activity in heavily pre-treated patients with solid tumors resistant to anti-VEGF therapies. Elpiscience holds Greater China rights.
  • ES002 Potentially best-in-class anti-CD39 monoclonal antibody that reverses suppressive tumor microenvironment by blocking CD39 function, stabilizing pro-inflammatory extracellular ATP (eATP), and restoring anti-tumor immunity. Internally discovered by Elpiscience.
  • ES014 First-in-class anti-CD39xTGF-β bispecific antibody that simultaneously targets CD39-adenosine and TGF-β pathways. Designed to create an immune-favorable tumor microenvironment by inhibiting adenosine generation and neutralizing immunosuppressive TGF-β. Received FDA Orphan Drug Designation for desmoid tumors.
  • ES009 Anti-LILRB2 (ILT4) monoclonal antibody that reprograms immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages. Demonstrated best-in-class potential in preclinical studies with ability to reverse immune suppression in tumor microenvironment. First-in-human studies conducted in Australia.
  • ES019 (BiME®) PD-L1/SIRPα bispecific antibody generated from proprietary BiME® platform. Simultaneously reactivates macrophages and T cells for tumor elimination by targeting both tumor cells and immune cells. Out-licensed to Astellas for development and commercialization outside Greater China.
  • ES004 Anti-SIRPα antibody with unique pan-allelic binding properties (ES004-B4 and ES004-N4 variants). Blocks CD47-SIRPα 'don't eat me' signaling and enhances macrophage-mediated tumor cell destruction through different mechanisms.
  • ES015 First-in-class NKG2A and NKG2C dual-targeting antibody that inhibits NKG2A function while promoting NKG2C action, leading to superior anti-tumor response through NK and CD8 T cell activation.
  • ES038 Novel NK cell engager (NKCE) targeting LILRB4 on AML cells while simultaneously blocking inhibitory (NKG2A) and stimulating (NKG2C) receptors on NK cells. Dual-targeting strategy enhances NK cell activation for AML treatment.
  • ES302 Next-generation bispecific antibody targeting TL1A and IL23p19 for inflammatory bowel disease (IBD) therapy. Dual-targeting approach blocks two critical cytokine pathways with engineered subcutaneous administration, long-acting profile, and superior resistance to enzymatic degradation.

Quantifiable outcome

  • ES104 achieved 19% ORR at RP2D (10.0-12.5 mg/kg) with 69% DCR in heavily pre-treated patients with colorectal and gastric cancers
  • +3 more outcomes

Companies that use Elpiscience Biopharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Elpiscience Biopharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Elpiscience Biopharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and minor.

  • Astellas Pharma Inc.majorStrategic or Co-development Partner · 28 December 2023Research collaboration and license agreement for novel bi-specific macrophage engagers (BiME), ES019 and another program. Companies will collaboratively conduct early-stage research. Elpiscience grants Astellas the right to add up to two additional programs. If Astellas exercises its option, Elpiscience will grant exclusive rights to further research, develop, manufacture and commercialize.
  • Compass Therapeutics (formerly TRIGR Therapeutics)majorStrategic or Co-development Partner · 20 January 2021Exclusive licensing agreement for ES104/TR009 in Greater China for development, manufacture and commercialization. TRIGR received $7 million upfront and eligible for $110 million in milestones plus royalties. Elpiscience leads clinical development in Greater China leveraging translational science, clinical and regulatory experience.
  • Junshi BiosciencesmajorStrategic or Co-development Partner · 28 May 2020Clinical collaboration to evaluate ES102 (next-generation OX40 agonistic antibody) in combination with toripalimab (TUOYI, anti-PD-1 mAb) for treatment of solid tumors and hematological malignancies.
  • Shanghai R&D Center (Zhangjiang High-Tech Park)minorOthers · 16 July 2019R&D center location in Zhangjiang High-Tech Park, China's most advanced innovation center for biomedical industry.
  • Inhibrx, Inc.majorOEM/ Whitelabel/ Licensing Partner · 1 March 2018Exclusive licensing agreement for ES101 (INBRX-105/PD-L1 and 4-1BB bispecific) in Greater China. Also partnered on ES102 (INBRX-106/hexavalent OX40 agonist) in Greater China.

Scale indicators3 records

Recent moves9 records

Expansion highlights6 records

Elpiscience Biopharmaceuticals competitors and assessment

Company assessment

Direct peers

  • I-Mab Biopharma: China- and US-based clinical-stage biopharmaceutical company focused on immuno-oncology biologics. I-Mab's pipeline of monoclonal and bispecific antibodies targeting similar pathways (CD47, PD-L1, 4-1BB) overlaps with Elpiscience's programs.
  • Akeso, Inc. China-based clinical-stage biopharmaceutical company developing a broad pipeline of innovative bispecific and multispecific antibodies for oncology and autoimmune diseases. Akeso is a leading domestic competitor in the Chinese bispecific antibody space with overlapping therapeutic targets.
  • CStone Pharmaceuticals: China-based clinical-stage biopharmaceutical company developing immuno-oncology agents including PD-L1 antibody (sugemalimab) and bispecifics. CStone competes with Elpiscience in the Chinese immuno-oncology market with overlapping indications.
  • Alphamab Oncology: China-based clinical-stage biopharmaceutical company focused on bispecific antibodies and antibody-drug conjugates for oncology. Alphamab has overlapping platform technologies (knob-into-hole bispecifics) and competes in similar indications including solid tumors.
  • Compass Therapeutics: Boston-based clinical-stage bispecific antibody developer and direct partner of Elpiscience (holds global ex-Greater China/South Korea rights to ES104). Compass has a similar pipeline of next-generation immuno-oncology bispecifics including CTX-009/ES104, making it a directly comparable peer.
  • Genor Biopharma: China-based biopharmaceutical company developing innovative therapeutics for oncology and autoimmune diseases, with a pipeline of monoclonal antibodies and bispecifics. Comparable in stage and therapeutic focus to Elpiscience's clinical-stage portfolio.
  • Inhibrx, Inc. Clinical-stage biotechnology company developing next-generation biologics including bispecific antibodies. Inhibrx is a direct licensor/partner of Elpiscience (ES101/INBRX-105 and ES102/INBRX-106 for Greater China) with highly comparable single-domain antibody platform technology.

Broad incumbents

  • BeiGene, Ltd. Global oncology-focused biotechnology company with approved BTK inhibitor (zanubrutinib) and PD-1 antibody (tislelizumab). While broader in scope than Elpiscience, BeiGene represents a major Chinese biopharma competitor with significantly greater commercialization scale and resources.

Emerging players

  • Junshi Biosciences: China-based innovation-driven biopharmaceutical company and Elpiscience's collaboration partner (ES102 + toripalimab combinations). Junshi's anti-PD-1 antibody toripalimab anchors multiple combination strategies in solid tumors, overlapping with Elpiscience's combination development.
  • NextCure, Inc. US-based clinical-stage immuno-oncology company developing novel biologics targeting myeloid immune checkpoints. NextCure's focus on tumor microenvironment and innate immunity modulation overlaps with Elpiscience's BiME® macrophage-engager approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Elpiscience Biopharmaceuticals social profiles

Digital presence

Elpiscience Biopharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elpiscience Biopharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Elpiscience Biopharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elpiscience Biopharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elpiscience Biopharmaceuticals

What does Elpiscience Biopharmaceuticals do?

Elpiscience is a clinical-stage biopharmaceutical company that develops next-generation immunotherapies for oncology and autoimmune diseases. Its core offering is a pipeline of innovative bispecific and monoclonal antibody therapeutics targeting immune checkpoints, the tumor microenvironment, and key cytokine pathways, generated through its proprietary BiME® macrophage engager platform and integrated antibody discovery engine. The company advances these programs through preclinical and clinical development with global strategic partners.

Is Elpiscience Biopharmaceuticals a public or private company?

Elpiscience Biopharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elpiscience Biopharmaceuticals founded?

Elpiscience Biopharmaceuticals was founded in 2017. It employs 11 to 50 people.

Where is Elpiscience Biopharmaceuticals based?

Elpiscience Biopharmaceuticals is headquartered in Shanghai, China, in the Asia region.

How does Elpiscience Biopharmaceuticals make money?

One revenue line is on record: drug Development and Commercialization.

Who are Elpiscience Biopharmaceuticals's main competitors?

Direct peers on record are I-Mab Biopharma, Akeso, Inc., CStone Pharmaceuticals, Alphamab Oncology, Compass Therapeutics, Genor Biopharma and Inhibrx, Inc.. BeiGene, Ltd. is listed as a broad incumbent. Emerging players are Junshi Biosciences and NextCure, Inc..

Does Elpiscience Biopharmaceuticals have an API?

No public API is recorded for Elpiscience Biopharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldElpiscience’s bispecific antibody ES-302 reduces disease activity in IBD modelElpiscience Biopharmaceuticals developed a bispecific antibody ES-302 targeting TL1A/DR3 and IL-23p19 for IBD treatment. In an IBD model, ES-302 reduced disease activity, supporting the hypothesis that dual targeting reshapes the immune landscape.BioCenturyElpiscience builds out global pipeline with CD39 focusElpiscience Biopharma is pursuing a dual-track strategy, in-licensing molecules for the China market while developing a broad immuno-oncology pipeline led by a CD39 franchise. The company launched in 2017 with a business model focused on licensing Western molecules for Greater China.PR NewswireTRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGFTRIGR Therapeutics and Elpiscience Biopharmaceuticals announced a $117 million exclusive licensing agreement for TR009, a Phase 1B dual angiogenic bispecific antibody targeting DLL4/VEGF, covering mainland China, Hong Kong, Macau, and Taiwan. TRIGR will receive $7 million upfront with additional development and commercial milestones of $110 million plus royalties on net sales. Phase 1 data demonstrates a 67% Clinical Benefit Rate in heavily pre-treated colorectal and gastric cancer patients who failed multiple lines of prior therapy.PR NewswireElpiscience and Bio-Techne Announce Strategic CollaborationElpiscience BioPharma and Bio-Techne Corporation announced a strategic collaboration for the development of anti-cancer therapeutics. Under the agreement, Elpiscience will gain access to multiple antibodies from Bio-Techne's product portfolio for use in preclinical, clinical, and commercial biopharmaceutical development. The collaboration aims to accelerate the development of new biologics to address unmet medical needs in oncology by combining Elpiscience's cancer immunotherapy expertise with Bio-Techne's extensive antibody library.